MRI Radiomics Signatures of 21-Gene Recurrence Score for Predicting Survival in ER+/HER2- Breast Cancer.

ABSTRACT:

Background

Oncotype DX 21-gene assays are recommended for evaluating distant recurrence and guiding decisions on the use of adjuvant therapy in ER+/HER2- breast cancers. However, it cannot be widely applied due to the high cost and time consumption.

Purpose

To identify MRI radiomics signatures within tumor and peritumoral tissues associated with the 21-gene recurrence score (RS) and explore their value in predicting 5-year recurrence in young women with ER+/HER2- breast cancer.

Methods

Two datasets were analyzed; all the enrolled patients were diagnosed with ER+/HER2- breast cancers and underwent preoperative breast MRIs. The radiogenomic development dataset, with RS data obtained from April 2017 to March 2019, was used to identify optimal RS-signatures based on tumor

SUBMITTER: Chen Y 

PROVIDER: S-EPMC12403013 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature